Company intelligence / Profile preview
Tavotek Biotherapeutics
Lower Gwynedd, Pennsylvania, United Statestavotek.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Tavotek has multiple assets in clinical development. TAVO101 is in Phase 2 for severe atopic dermatitis. TAVO412 (a multispecific biologic targeting EGFR, VEGF, and c-Met) and TAVO421 are in Phase 1 for solid tumors. The company has successfully dosed patients in clinical trials for TAVO103A and TAVO101, transforming it from a preclinical to a clinical-stage company.
- Therapeutic areas
- OncologyImmunologyDermatologyPulmonology
- Modalities
- Monoclonal antibodiesBispecific antibodiesTrispecific antibodiesAntibody Fragment-Drug Conjugates (FDCs)Bispecific T-cell Engager (BiTE)
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
Beyond the preview
Go deeper on Tavotek Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tavotek Biotherapeutics.